scholarly journals Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Haematologica ◽  
2021 ◽  
Author(s):  
John N. Allan ◽  
Javier Pinilla-Ibarz ◽  
Douglas E. Gladstone ◽  
Krish Patel ◽  
Jeff P. Sharman ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
B Cell ◽  
Tyrosine Kinase Inhibitor ◽  
Dose Escalation ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
B Cell Malignancies ◽  
Dose Escalation Study ◽  
Bruton's Tyrosine Kinase ◽  
Phase 1B

Not available.

scholarly journals Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies

2015 ◽  
Vol 1358 (1) ◽  
pp. 82-94 ◽  
Author(s):  
Urte Gayko ◽  
Mann Fung ◽  
Fong Clow ◽  
Steven Sun ◽  
Elizabeth Faust ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
B Cell ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
B Cell Malignancies ◽  
Bruton's Tyrosine Kinase
Sign in / Sign up

Export Citation Format

Share Document